StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 5.0
Power Rank trend -> Rising
04/25/2025 14:17:00 EST
Adaptive Biotechnologies Corp (ADPT)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, ADPT has been trading in a range between $8.66 and $7.41 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Adaptive Biotechnologies Corp $ADPT entered a Red zone 2 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $7.5833, a potential upside of 3.46% from the recent price of 7.33. The stock is trading 22.92% (potential upside) below its 52 week high of $9.01 and 210.59 % (potential downside) above its 52 week low of $2.36 - based on the recent price.
Company Summary
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
News
| Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Source: GlobeNewsWire Thu, 10 Apr 2025 16:05:00 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission Source: GlobeNewsWire Tue, 08 Apr 2025 08:00:00 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA). The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity. Source: GlobeNewsWire Tue, 11 Mar 2025 08:00:00 -0400 Sentiment: Neutral |
| Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Source: Zacks Investment Research Wed, 12 Feb 2025 13:01:17 -0500 Sentiment: Positive |
| Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year. Source: Zacks Investment Research Wed, 12 Feb 2025 10:40:15 -0500 Sentiment: Negative |
Technicals 52 Week Hi: 9.01 52 Week Low: 2.56 Beta: 1.73 50 Day MA: 7.8269 200 Day MA: 6.023 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.037 Forward PE: 0 Trailing PE: 0